How Does Pylopass Effectively Reduce H. Pylori Load?

Helicobacter pylori (H. pylori) Conventional Treatment

  • Eradication with 2-3 antibiotics and a proton pump inhibitor
  • There are no global or country specific total eradication programs instituted for H. pylori
  • Increased resistance against antibiotics leads to the decrease of success rate from 90 to 75% to date
  • Severe side-effects such as nausea, vomiting, digestive disorders and headache are observed
  • High risk of re-infection


Unfortunately, many people suffer side effects from the conventional therapy. The side effects may include diarrhoea, nausea, a metallic taste and sometimes a severe inflammation of the bowel.

If you stop half way through a course, your ulcer and all the problems that occur as a result of it will return. You may also be left with a drug-resistant strain of H. pylori that cannot easily be treated with further antibiotics. If you cannot tolerate the side effects of treatment you should check with your doctor before stopping the course.

Long-term ulcer sufferers are at risk of perforation of the lining of the stomach or duodenum and are also at risk of bleeding from the gastrointestinal tract. There is also increasing evidence that infection with H. pylori is associated with cancer of the stomach. Therefore, it is important to identify and treat H. pylori infection.

First-line therapy: Triple Therapy

In areas of low clarithromycin resistance, including the United States, a 14-day course of “triple therapy, ” with an oral proton pump inhibitor, clarithromycin 500 mg, and amoxicillin 1 g (or, if penicillin allergic, metronidazole 500 mg), all given twice daily for 14 days, is still recommended for first-line therapy. Unfortunately, this regimen only achieves rates of eradication > 75%.

Second-line therapy: Quadruple Therapy

With a proton pump inhibitor, bismuth, tetracycline, and metronidazole or tinidazole for 14 days.



Pylopass™ Human Study

Pylopass works in a completely new and different way. Helicobacter pylori is a problem because it sticks to the mucosa of the stomach or duodenal wall, secreting chemicals that damage the lining. European scientists found that Pylopass could agglomerate the bacteria, causing them to ball up in clumps that cannot stick to the stomach or duodenal wall, and so stopping them causing ulcers. Clumped together in this way, they can just pass through the digestive system harmlessly.

  • Pylopass™ pilot study conducted in Berlin, Germany.
  • Design: Single-blinded cross over study.
  • n = 22 H. pylori positive, asymptomatic adults (mean age: 47).
  • Primary outcome: H. pylori load after 2 week Pylopass supplementation as measured by urea breath test (UBT).


Using the extremely accurate (98%) and non invasive Urea Breath Test (UBT), which involves drinking a small amount of labeled urea solution and then breathing into a test tube, a clinical trial showed statistically significant results. Placebo: 3% change in UBT from baseline Pylopass: 16% change in UBT from baseline.